Publications
Publications
Show Results For
- All HBS Web
(6,826)
- Faculty Publications (2,004)
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
- August 2023
- Technical Note
Two Ways of Pursuing a Calling
By: Leslie Perlow and Hannah Weisman
Work can be a means to a financial end, a stepping stone to higher-level jobs, or a meaningful end in itself: a calling. The technical note provides an overview of two different ways people can pursue a calling: with an internal focus or external focus. View Details
- August 2023
- Teaching Note
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
Teaching Note for HBS Case No. 724-373. View Details
- August 2023
- Case
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
- August 2023 (Revised August 2023)
- Case
Sky Therapeutics: Innovating in Digital Therapeutics
By: Satish Tadikonda, Olivia Reszczynski and William Marks
Shad Faraz and Alex Youssef were intrigued by the opportunities in the relatively new area of Digital Therapeutics. Despite initial successes, early entrants had struggled with reimbursement and revenue-predictability challenges. However, venture investors still... View Details
- 2023
- Article
Evidence from the First Shared Medical Appointments (SMAs) Randomised Controlled Trial in India: SMAs Increase the Satisfaction, Knowledge, and Medication Compliance of Patients with Glaucoma
By: Nazlı Sönmez, Kavitha Srinivasan, Rengaraj Venkatesh, Ryan W. Buell and Kamalini Ramdas
In Shared Medical Appointments (SMAs), patients with similar conditions meet the physician together and each receives one-on-one attention. SMAs can improve outcomes and physician productivity. Yet privacy concerns have stymied adoption. In physician-deprived nations,... View Details
- July 2023
- Case
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold... View Details
- July 2023
- Article
Deep Responsibility and Irresponsibility in the Beauty Industry
By: Geoffrey Jones
This article employs the concept of deep responsibility to assess the social responsibility of the beauty industry over time. It shows that many of today’s problems with the industry have deep historical roots. Products have too many ingredients that are potential... View Details
- Summer 2023
- Article
Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?
By: Eric Barrette, Leemore S. Dafny and Karen Shen
Even among commercially insured individuals, opioid use disorder is undertreated in the United States: nearly half receive no treatment within six months of a new diagnosis. Using a difference-in-differences specification exploiting the extension of insurance parity... View Details
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
- June 2023
- Supplement
Roche: ESG and Access to Healthcare
By: George Serafeim
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details
Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Health Industry; Health Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
- June 2023 (Revised November 2023)
- Case
Sober Sidekick
By: Jeffrey J. Bussgang and Kumba Sennaar
Case on the nascent business model of a mobile health IT startup. In particular, should they pivot away from their successful lead generation business model to charging health plans. View Details
- 3 Jun 2023
- Talk
Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
- June 2023
- Teaching Note
From Cradle to Heaven: Taikang Insurance Group
By: William C. Kirby and Noah B. Truwit
Teaching Note for HBS Case No. 320-088. The case explores the rise of Taikang Insurance Group and its quest to be a leader of one of China's fastest-growing industries. Due to China's underdeveloped social welfare state, Taikang saw an opportunity for the private... View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023
- Article
A Public Health Approach to Negative News Media: The 3-to-1 Solution
By: Tyler VanderWeele and Arthur C. Brooks
There is clear evidence that the prevalence of negative media reporting has increased substantially over the past years. There is evidence also that this negative reporting adversely affects social interactions, as well as health and well-being outcomes. Given the wide... View Details